查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108327

新冠病毒檢測試劑盒市場分析與預測（至2035年）：類型、產品類型、技術、組件、應用、部署模式、最終用戶、使用模式、階段

COVID-19 Detection Kits Market Analysis and Forecast to 2035: Type, Product, Technology, Component, Application, Deployment, End User, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球新冠病毒檢測試劑盒市場預計將從2025年的54億美元成長至2035年的34億美元，複合年成長率為-4.6%。該市場集中度適中，其中基於PCR技術的試劑盒憑藉其較高的診斷準確性和在確診檢測中的持續應用，佔了最大的市場佔有率。同時，快速抗原檢測套組在分散式和照護現場篩檢中也被廣泛應用。呼吸道疾病監測、多分子診斷以及應對未來感染疾病疫情的準備工作，日益推動了市場需求。該市場的特點是RT-PCR、等溫擴增和快速免疫檢測技術的持續創新，以及自動化檢測流程和數位化報告系統的整合。製造商也在努力開發能夠檢測單一檢體中多種呼吸道病原體的多重檢測方法。例如，羅氏公司於2025年8月獲得了FDA的510(k)批准，其cobas Respiratory 4-flex分子診斷試劑盒上市。該測試採用該公司TAGS技術，可同時檢測和區分SARS-CoV-2、甲型流感、乙型流感和RSV，從而促進從單劑量COVID-19檢測向綜合呼吸系統疾病診斷的轉變，並加強分子診斷市場的創新。

按類型分類，預計到2025年，基於PCR的檢測試劑盒將主導COVID-19檢測市場。這主要歸功於其卓越的診斷準確性、高靈敏度以及作為SARS-CoV-2檢測參考標準的全球認可度。基於PCR的檢測試劑盒繼續廣泛應用於醫院、診斷檢查室和公共衛生檢查室，用於確診、監測和變異株監測。儘管常規檢測有所下降，但由於其低病毒載量檢測能力、與多重檢測的兼容性以及符合監管指南等特點，市場需求仍然強勁。在臨床診斷、感染疾病監測以及應對新發呼吸道病原體的準備工作中持續應用，進一步鞏固了該領域在已開發國家和開發中國家醫療保健系統中的主導地位。

市場區隔
類型 以 PCR 為基礎的試劑盒、以抗原為基礎的試劑盒、以抗體為基礎的試劑盒、等溫擴增試劑盒、以 CRISPR 為基礎的試劑盒等。
產品 試紙、試劑、拭子、品控試劑盒、緩衝液及其他物品。
科技 RT-PCR、LAMP、ELISA、橫向流動化驗、次世代定序等。
成分 檢體採集試劑盒、檢測試劑盒、萃取試劑盒、擴增試劑盒等。
目的 臨床檢測、家庭檢測、實驗室檢測、即時檢測、篩檢等。
實作方法 現場測試、遠端測試及其他服務。
最終用戶 醫院、診斷檢測實驗室、學術和研究機構、居家照護機構、公共衛生檢測實驗室等。
使用方法 專業人士使用、自我測驗等。
步 檢測、確診、篩檢、監測等。

按應用領域分類，「居家檢測」細分市場預計將在預測期內實現最快成長，這主要得益於消費者對便利、快速和自測診斷解決方案日益成長的需求。快速抗原自測檢測套組的普及、居家醫療意識的提高以及零售和電商分銷管道的擴張，持續推動著居家檢測的普及。政府推廣分散式檢查的舉措，以及方便用戶使用型診斷格式和數位化結果報告的進步，也在加速市場成長。此外，居家檢測還能減輕醫療機構的負擔，有助於快速制定適當的隔離措施，並支持在後疫情時代對呼吸道感染疾病進行持續監測。

區域概覽

2025年，北美憑藉其先進的醫療基礎設施、完善的分子診斷檢查室和健全的公共衛生監測系統，主導了新冠病毒檢測試劑盒市場。美國佔了最大的區域市場佔有率，這得益於其在感染疾病控制方面的持續投入、RT-PCR和多參數呼吸道檢測的廣泛應用，以及眾多主要診斷試劑生產商的存在。加拿大也透過政府支持的疾病監測計畫和檢查室現代化舉措做出了重要貢獻。儘管常規新冠病毒檢測的數量有所下降，但對呼吸道病原體檢測、醫院診斷和疫情應對的持續需求，仍支撐著該地區的主導地位。

預計亞太地區將在預測期內實現最快成長，這主要得益於醫療基礎設施的不斷改進、分子診斷投資的增加以及感染疾病監測計畫的加強。中國、印度和日本是關鍵的成長市場，這得益於其龐大的人口基數、不斷擴展的診斷檢查室網路以及快速和分子檢測技術的日益普及。政府為加強疫情防範所做的努力、國內診斷試劑盒產量的增加以及多參數呼吸道檢測在常規臨床實踐中的應用，都進一步加速了市場擴張。醫療保健支出的成長和先進診斷技術的普及，持續全部區域創造了巨大的成長機會。

主要趨勢和促進因素

擴大多參數呼吸系統診斷測試的應用範圍：

新冠病毒檢測試劑盒市場正從單一的SARS-CoV-2檢測轉變為多重分子診斷轉變，後者能夠在一次檢測中同時檢測多種呼吸道病原體，包括甲型和乙型流感病毒以及呼吸道融合細胞病毒（RSV）。醫療機構和診斷實驗室正擴大採用這些解決方案，以提高臨床決策的準確性、減輕檢查室工作量，並在呼吸道感染疾病爆發期間提升檢測效率。 RT-PCR、等溫擴增和自動化分子診斷平台的持續進步進一步推動了這一轉變。隨著對綜合呼吸道疾病監測和疫情應變的日益重視，對先進多重檢測試劑盒的需求預計將持續成長。

增加對感染疾病監測和疫情應變的投入：

各國政府、醫療機構和公共衛生組織正在增加對感染疾病監測基礎設施和診斷系統的投入，以增​​強應對未來感染疾病疫情的能力。分子診斷檢查室的擴建、檢測材料的戰略儲備以及公共衛生檢查室網路的現代化，持續推動新冠病毒檢測試劑盒及相關診斷技術的需求。分散式檢查的日益普及、人們對疾病早期檢測意識的提高以及對檢查室自動化和基因組監測的持續投入，進一步加速了市場成長，並為應對新發感染疾病的長期準備工作提供了支持。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 基於PCR的試劑盒
    • 基於抗原的試劑盒
    • 抗體試劑盒
    • 等溫擴增試劑盒
    • 基於 CRISPR 的試劑盒
    • 其他
  • 市場規模及預測：依產品分類
    • 測試條
    • 試劑
    • 棉花棒
    • 品質控制套件
    • 緩衝
    • 其他
  • 市場規模及預測：依技術分類
    • RT-PCR
    • LAMP
    • ELISA
    • 橫向流動化驗
    • 次世代定序
    • 其他
  • 市場規模及預測：依應用領域分類
    • 臨床檢測
    • 家庭測試
    • 研究所
    • 照護現場
    • 篩檢
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診斷檢查室
    • 學術研究機構
    • 居家照護
    • 公共衛生研究所
    • 其他
  • 市場規模及預測：依組件分類
    • 檢體採集工具包
    • 檢測套件
    • 提取套件
    • 放大套件
    • 其他
  • 市場規模及預測：依用途類型分類
    • 商用
    • 自我診斷
    • 其他
  • 市場規模及預測：依階段分類
    • 偵測
    • 確認
    • 篩檢
    • 監測
    • 其他
  • 市場規模及預測：依部署方式分類
    • 現場檢查
    • 遠端測試
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Roche Diagnostics
  • Abbott Laboratories
  • Thermo Fisher Scientific
  • Siemens Healthineers
  • Becton Dickinson
  • Bio-Rad Laboratories
  • Qiagen
  • Hologic
  • PerkinElmer
  • Danaher Corporation
  • bioMerieux
  • Cepheid
  • Luminex Corporation
  • Quidel Corporation
  • GenMark Diagnostics
  • OraSure Technologies
  • F. Hoffmann-La Roche
  • Meridian Bioscience
  • Seegene
  • Tecan Group

第9章 關於我們

簡介目錄
Product Code: GIS10525

The global COVID-19 Detection Kits Market is projected to grow from $5.4 billion in 2025 to $3.4 billion by 2035, at a compound annual growth rate (CAGR) of -4.6%. The COVID-19 Detection Kits Market is moderately consolidated, with PCR-based kits accounting for the largest share due to their high diagnostic accuracy and continued use in confirmatory testing, while rapid antigen kits remain widely adopted for decentralized and point-of-care screening. Demand is increasingly supported by respiratory disease surveillance, multiplex molecular diagnostics, and preparedness for future infectious disease outbreaks. The market is characterized by continuous innovation in RT-PCR, isothermal amplification, and rapid immunoassay technologies, alongside the integration of automated laboratory workflows and digital reporting systems. Manufacturers are also expanding multiplex assays capable of detecting multiple respiratory pathogens using a single sample. For instance, in August 2025, Roche received U.S. FDA 510(k) clearance for its cobas Respiratory 4-flex molecular assay, which simultaneously detects and differentiates SARS-CoV-2, Influenza A, Influenza B, and RSV using its TAGS technology, strengthening the transition from standalone COVID-19 testing to comprehensive respiratory diagnostics and reinforcing innovation in the molecular diagnostics market.

Based on Type, the PCR-based Kits segment dominated the COVID-19 Detection Kits Market in 2025, owing to its superior diagnostic accuracy, high sensitivity, and global recognition as the reference standard for SARS-CoV-2 detection. PCR-based kits remain extensively used across hospitals, diagnostic laboratories, and public health laboratories for confirmatory diagnosis, surveillance, and variant monitoring. Their ability to detect low viral loads, support multiplex testing, and comply with regulatory guidelines has sustained demand despite declining routine testing volumes. Continuous adoption in clinical diagnostics, infectious disease surveillance, and preparedness for emerging respiratory pathogens further reinforces the segment's dominant position across developed and developing healthcare systems.

Market Segmentation
TypePCR-based Kits, Antigen-based Kits, Antibody-based Kits, Isothermal Amplification Kits, CRISPR-based Kits, Others
ProductTest Strips, Reagents, Swabs, Control Kits, Buffers, Others
TechnologyRT-PCR, LAMP, ELISA, Lateral Flow Assay, Next-Generation Sequencing, Others
ComponentSample Collection Kits, Detection Kits, Extraction Kits, Amplification Kits, Others
ApplicationClinical Testing, Home Testing, Research Laboratories, Point of Care, Screening, Others
DeploymentOn-site Testing, Remote Testing, Others
End UserHospitals, Diagnostic Laboratories, Academic and Research Institutes, Home Care, Public Health Labs, Others
ModeProfessional Use, Self-Testing, Others
StageDetection, Confirmation, Screening, Monitoring, Others

Based on Application, the Home Testing segment is expected to register the fastest growth during the forecast period, driven by increasing consumer preference for convenient, rapid, and self-administered diagnostic solutions. The widespread availability of rapid antigen self-test kits, growing awareness of home-based healthcare, and expanding retail and e-commerce distribution channels continue to support adoption. Government initiatives promoting decentralized testing, along with advancements in easy-to-use diagnostic formats and digital result reporting, are accelerating market growth. Home testing also reduces healthcare facility burden, enables timely isolation decisions, and supports ongoing monitoring of respiratory infectious diseases beyond the COVID-19 pandemic.

Geographical Overview

North America dominated the COVID-19 Detection Kits Market in 2025, supported by its advanced healthcare infrastructure, well-established molecular diagnostic laboratories, and strong public health surveillance systems. The United States accounted for the largest regional share due to continued investments in infectious disease preparedness, widespread adoption of RT-PCR and multiplex respiratory testing, and the presence of leading diagnostic manufacturers. Canada also contributes significantly through government-backed disease surveillance programs and laboratory modernization initiatives. Although routine COVID-19 testing volumes have declined, sustained demand for respiratory pathogen panels, hospital diagnostics, and outbreak preparedness continues to support the region's leadership.

Asia-Pacific is expected to register the fastest growth during the forecast period, driven by expanding healthcare infrastructure, increasing investments in molecular diagnostics, and strengthening infectious disease surveillance programs. China, India, and Japan are the key growth markets due to their large populations, expanding diagnostic laboratory networks, and rising adoption of rapid and molecular testing technologies. Government initiatives to improve pandemic preparedness, growing domestic manufacturing of diagnostic kits, and increasing integration of multiplex respiratory testing into routine clinical practice are further accelerating market expansion. Rising healthcare expenditure and improved access to advanced diagnostic technologies continue to create significant growth opportunities across the region.

Key Trends and Drivers

Increasing Adoption of Multiplex Respiratory Diagnostic Testing:

The COVID-19 detection kits market is evolving from standalone SARS-CoV-2 testing toward multiplex molecular diagnostics capable of detecting multiple respiratory pathogens, including influenza A/B and respiratory syncytial virus (RSV), through a single assay. Healthcare providers and diagnostic laboratories are increasingly adopting these solutions to improve clinical decision-making, reduce laboratory workload, and enhance testing efficiency during respiratory infection seasons. Continuous advancements in RT-PCR, isothermal amplification, and automated molecular platforms are further supporting this transition. The growing emphasis on integrated respiratory disease surveillance and pandemic preparedness is expected to sustain demand for advanced multiplex detection kits.

Growing Investments in Infectious Disease Surveillance and Pandemic Preparedness:

Governments, healthcare organizations, and public health agencies are increasing investments in infectious disease surveillance infrastructure and diagnostic preparedness to strengthen future outbreak response capabilities. The expansion of molecular diagnostic laboratories, strategic stockpiling of testing supplies, and modernization of public health laboratory networks are driving continued demand for COVID-19 detection kits and related diagnostic technologies. Rising adoption of decentralized testing, increasing awareness of early disease detection, and continuous funding for laboratory automation and genomic surveillance are further accelerating market growth while supporting long-term preparedness against emerging infectious diseases.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Component
  • 2.7 Key Market Highlights by Mode
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Deployment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 PCR-based Kits
    • 4.1.2 Antigen-based Kits
    • 4.1.3 Antibody-based Kits
    • 4.1.4 Isothermal Amplification Kits
    • 4.1.5 CRISPR-based Kits
    • 4.1.6 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Test Strips
    • 4.2.2 Reagents
    • 4.2.3 Swabs
    • 4.2.4 Control Kits
    • 4.2.5 Buffers
    • 4.2.6 Others
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 RT-PCR
    • 4.3.2 LAMP
    • 4.3.3 ELISA
    • 4.3.4 Lateral Flow Assay
    • 4.3.5 Next-Generation Sequencing
    • 4.3.6 Others
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Clinical Testing
    • 4.4.2 Home Testing
    • 4.4.3 Research Laboratories
    • 4.4.4 Point of Care
    • 4.4.5 Screening
    • 4.4.6 Others
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Diagnostic Laboratories
    • 4.5.3 Academic and Research Institutes
    • 4.5.4 Home Care
    • 4.5.5 Public Health Labs
    • 4.5.6 Others
  • 4.6 Market Size & Forecast by Component (2020-2035)
    • 4.6.1 Sample Collection Kits
    • 4.6.2 Detection Kits
    • 4.6.3 Extraction Kits
    • 4.6.4 Amplification Kits
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Mode (2020-2035)
    • 4.7.1 Professional Use
    • 4.7.2 Self-Testing
    • 4.7.3 Others
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Detection
    • 4.8.2 Confirmation
    • 4.8.3 Screening
    • 4.8.4 Monitoring
    • 4.8.5 Others
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 On-site Testing
    • 4.9.2 Remote Testing
    • 4.9.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Component
      • 5.2.1.7 Mode
      • 5.2.1.8 Stage
      • 5.2.1.9 Deployment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Component
      • 5.2.2.7 Mode
      • 5.2.2.8 Stage
      • 5.2.2.9 Deployment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Component
      • 5.2.3.7 Mode
      • 5.2.3.8 Stage
      • 5.2.3.9 Deployment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Component
      • 5.3.1.7 Mode
      • 5.3.1.8 Stage
      • 5.3.1.9 Deployment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Component
      • 5.3.2.7 Mode
      • 5.3.2.8 Stage
      • 5.3.2.9 Deployment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Component
      • 5.3.3.7 Mode
      • 5.3.3.8 Stage
      • 5.3.3.9 Deployment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Component
      • 5.4.1.7 Mode
      • 5.4.1.8 Stage
      • 5.4.1.9 Deployment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Component
      • 5.4.2.7 Mode
      • 5.4.2.8 Stage
      • 5.4.2.9 Deployment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Component
      • 5.4.3.7 Mode
      • 5.4.3.8 Stage
      • 5.4.3.9 Deployment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Component
      • 5.4.4.7 Mode
      • 5.4.4.8 Stage
      • 5.4.4.9 Deployment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Component
      • 5.4.5.7 Mode
      • 5.4.5.8 Stage
      • 5.4.5.9 Deployment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Component
      • 5.4.6.7 Mode
      • 5.4.6.8 Stage
      • 5.4.6.9 Deployment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Component
      • 5.4.7.7 Mode
      • 5.4.7.8 Stage
      • 5.4.7.9 Deployment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Component
      • 5.5.1.7 Mode
      • 5.5.1.8 Stage
      • 5.5.1.9 Deployment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Component
      • 5.5.2.7 Mode
      • 5.5.2.8 Stage
      • 5.5.2.9 Deployment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Component
      • 5.5.3.7 Mode
      • 5.5.3.8 Stage
      • 5.5.3.9 Deployment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Component
      • 5.5.4.7 Mode
      • 5.5.4.8 Stage
      • 5.5.4.9 Deployment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Component
      • 5.5.5.7 Mode
      • 5.5.5.8 Stage
      • 5.5.5.9 Deployment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Component
      • 5.5.6.7 Mode
      • 5.5.6.8 Stage
      • 5.5.6.9 Deployment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Component
      • 5.6.1.7 Mode
      • 5.6.1.8 Stage
      • 5.6.1.9 Deployment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Component
      • 5.6.2.7 Mode
      • 5.6.2.8 Stage
      • 5.6.2.9 Deployment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Component
      • 5.6.3.7 Mode
      • 5.6.3.8 Stage
      • 5.6.3.9 Deployment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Component
      • 5.6.4.7 Mode
      • 5.6.4.8 Stage
      • 5.6.4.9 Deployment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Component
      • 5.6.5.7 Mode
      • 5.6.5.8 Stage
      • 5.6.5.9 Deployment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Roche Diagnostics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Abbott Laboratories
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Thermo Fisher Scientific
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Siemens Healthineers
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Becton Dickinson
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Bio-Rad Laboratories
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Qiagen
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Hologic
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 PerkinElmer
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Danaher Corporation
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 bioMerieux
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Cepheid
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Luminex Corporation
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Quidel Corporation
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 GenMark Diagnostics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 OraSure Technologies
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 F. Hoffmann-La Roche
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Meridian Bioscience
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Seegene
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Tecan Group
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us